IBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Warning Sign:
Beneish M-Score -1.16 higher than -1.78, which implies that the company might have manipulated its financial results.
The historical rank and industry rank for iBio's Beneish M-Score or its related term are showing as below:
During the past 13 years, the highest Beneish M-Score of iBio was 62.02. The lowest was -12.55. And the median was -2.28.
The historical data trend for iBio's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iBio Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | Jun24 | |||||||||||
Beneish M-Score | Get a 7-Day Free Trial | 62.02 | -0.97 | 0.06 | - | - |
iBio Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Beneish M-Score | Get a 7-Day Free Trial | -12.55 | -7.90 | - | - | -1.16 |
For the Biotechnology subindustry, iBio's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, iBio's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where iBio's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of iBio for today is based on a combination of the following eight different indices:
M | = | -4.84 | + | 0.92 * DSRI | + | 0.528 * GMI | + | 0.404 * AQI | + | 0.892 * SGI | + | 0.115 * DEPI |
= | -4.84 | + | 0.92 * 1 | + | 0.528 * 1 | + | 0.404 * 1.3915 | + | 0.892 * 3.5 | + | 0.115 * 0.8611 | |
- | 0.172 * SGAI | + | 4.679 * TATA | - | 0.327 * LVGI | |||||||
- | 0.172 * 0.1787 | + | 4.679 * -0.29453 | - | 0.327 * 0.4319 | |||||||
= | -1.16 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Sep24) TTM: | Last Year (Sep23) TTM: |
Total Receivables was $0.00 Mil. Revenue was 0 + 0.175 + 0 + 0 = $0.18 Mil. Gross Profit was 0 + 0.175 + 0 + 0 = $0.18 Mil. Total Current Assets was $11.71 Mil. Total Assets was $24.52 Mil. Property, Plant and Equipment(Net PPE) was $6.10 Mil. Depreciation, Depletion and Amortization(DDA) was $1.21 Mil. Selling, General, & Admin. Expense(SGA) was $10.93 Mil. Total Current Liabilities was $3.47 Mil. Long-Term Debt & Capital Lease Obligation was $3.28 Mil. Net Income was -3.989 + -7.778 + -3.172 + -8.211 = $-23.15 Mil. Non Operating Income was 0 + 0 + 1 + 0 = $1.00 Mil. Cash Flow from Operations was -3.715 + -4.854 + -3.654 + -4.706 = $-16.93 Mil. |
Total Receivables was $0.00 Mil. Revenue was 0.05 + 0 + 0 + 0 = $0.05 Mil. Gross Profit was 0.05 + 0 + 0 + 0 = $0.05 Mil. Total Current Assets was $23.02 Mil. Total Assets was $37.68 Mil. Property, Plant and Equipment(Net PPE) was $7.24 Mil. Depreciation, Depletion and Amortization(DDA) was $1.20 Mil. Selling, General, & Admin. Expense(SGA) was $17.48 Mil. Total Current Liabilities was $20.71 Mil. Long-Term Debt & Capital Lease Obligation was $3.30 Mil. |
1. DSRI = Days Sales in Receivables Index
Measured as the ratio of Revenue in Total Receivables in year t to year t-1.
A large increase in DSR could be indicative of revenue inflation.
DSRI | = | (Receivables_t / Revenue_t) | / | (Receivables_t-1 / Revenue_t-1) |
= | (0 / 0.175) | / | (0 / 0.05) | |
= | 0 | / | 0 | |
= | 1 |
2. GMI = Gross Margin Index
Measured as the ratio of gross margin in year t-1 to gross margin in year t.
Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.
GMI | = | GrossMargin_t-1 | / | GrossMargin_t |
= | (GrossProfit_t-1 / Revenue_t-1) | / | (GrossProfit_t / Revenue_t) | |
= | (0.05 / 0.05) | / | (0.175 / 0.175) | |
= | 1 | / | 1 | |
= | 1 |
3. AQI = Asset Quality Index
AQI is the ratio of asset quality in year t to year t-1.
Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.
AQI | = | (1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) | / | (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1) |
= | (1 - (11.705 + 6.099) / 24.517) | / | (1 - (23.022 + 7.242) / 37.678) | |
= | 0.27381 | / | 0.196773 | |
= | 1.3915 |
4. SGI = Sales Growth Index
Ratio of Revenue in year t to sales in year t-1.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
SGI | = | Sales_t | / | Sales_t-1 |
= | Revenue_t | / | Revenue_t-1 | |
= | 0.175 | / | 0.05 | |
= | 3.5 |
5. DEPI = Depreciation Index
Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI | = | (Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) | / | (Depreciation_t / (Depreciaton_t + PPE_t)) |
= | (1.204 / (1.204 + 7.242)) | / | (1.21 / (1.21 + 6.099)) | |
= | 0.142553 | / | 0.165549 | |
= | 0.8611 |
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.
SGA expenses index > 1 means that the company is becoming less efficient in generate sales.
SGAI | = | (SGA_t / Sales_t) | / | (SGA_t-1 /Sales_t-1) |
= | (10.928 / 0.175) | / | (17.475 / 0.05) | |
= | 62.445714 | / | 349.5 | |
= | 0.1787 |
7. LVGI = Leverage Index
The ratio of total debt to Total Assets in year t relative to yeat t-1.
An LVGI > 1 indicates an increase in leverage
LVGI | = | ((LTD_t + CurrentLiabilities_t) / TotalAssets_t) | / | ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1) |
= | ((3.278 + 3.469) / 24.517) | / | ((3.3 + 20.708) / 37.678) | |
= | 0.275197 | / | 0.637189 | |
= | 0.4319 |
8. TATA = Total Accruals to Total Assets
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA | = | (IncomefromContinuingOperations_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
= | (NetIncome_t - NonOperatingIncome_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t | |
= | (-23.15 - 1 | - | -16.929) | / | 24.517 | |
= | -0.29453 |
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
iBio has a M-score of -1.16 signals that the company is likely to be a manipulator.
Thank you for viewing the detailed overview of iBio's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Martin Brenner | officer: Chief Scientific Officer | C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121 |
Felipe Duran | officer: Interim CFO | 8800 HSC PARKWAY, BRYAN TX 77807 |
William D Clark | director | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140 |
Evert B. Schimmelpennink | director | C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121 |
Isett Thomas Francis 3rd | director, officer: CEO and Executive Chairman | C/O IBIO INC. 600 MADISON AVENUE, SUITE 1601, NEW YORK NY 10022 |
Robert Matthew Lutz | officer: See Remarks | 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053 |
Randy Joe Maddux | officer: Chief Operating Officer | 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121 |
Alexandra Kropotova | director | RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807 |
Gary Sender | director | C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVE, NEW YORK NY 10020 |
Linda Washington Armstrong | director | 8800 HSC PARKWAY, BRYAN TX 77807 |
John Delta | officer: Principal Accounting Officer | 8800 HSC PARKWAY, BRYAN TX 77807 |
Eastern Capital Ltd | 10 percent owner | 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006 |
Robert L Erwin | officer: President | C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711 |
James P. Mullaney | officer: Chief Financial Officer | C/O IBIO, INC., 600 MADISON AVE., SUITE 1601, NEW YORK NY 10022 |
Carl Desantis | 10 percent owner | C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431 |
From GuruFocus
By PRNewswire • 12-05-2023
By GuruFocus News • 11-12-2024
By PRNewswire PRNewswire • 02-21-2023
By GuruFocus Research • 02-13-2024
By PRNewswire PRNewswire • 02-04-2021
By PRNewswire • 03-27-2024
By GuruFocus Research • 02-13-2024
By GuruFocus Research • 02-13-2024
By PRNewswire PRNewswire • 05-07-2021
By PRNewswire PRNewswire • 03-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.